Silverberg Bernstein Capital Management LLC Has $737,000 Stake in Accuray Incorporated (NASDAQ:ARAY)

Silverberg Bernstein Capital Management LLC lowered its position in Accuray Incorporated (NASDAQ:ARAY) by 10.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 372,452 shares of the medical equipment provider’s stock after selling 43,332 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Accuray were worth $737,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of ARAY. Assenagon Asset Management S.A. lifted its stake in Accuray by 28.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 212,330 shares of the medical equipment provider’s stock valued at $420,000 after purchasing an additional 47,331 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Accuray in the third quarter valued at approximately $244,000. Barclays PLC boosted its stake in shares of Accuray by 97.9% during the 3rd quarter. Barclays PLC now owns 210,819 shares of the medical equipment provider’s stock worth $380,000 after acquiring an additional 104,310 shares during the period. Geode Capital Management LLC increased its holdings in shares of Accuray by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,179,396 shares of the medical equipment provider’s stock worth $3,924,000 after acquiring an additional 45,548 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Accuray in the 3rd quarter valued at $249,000. Institutional investors own 64.08% of the company’s stock.

Accuray Price Performance

Shares of NASDAQ ARAY opened at $2.21 on Wednesday. The business’s 50 day moving average is $1.98 and its 200-day moving average is $1.92. The firm has a market cap of $222.25 million, a P/E ratio of -13.00 and a beta of 1.47. Accuray Incorporated has a 1-year low of $1.40 and a 1-year high of $2.99. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59.

Accuray (NASDAQ:ARAY) last released its earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. The firm had revenue of $101.55 million for the quarter, compared to analyst estimates of $98.10 million. During the same period last year, the firm earned ($0.03) EPS. Equities research analysts predict that Accuray Incorporated will post 0.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.